Can-Fite's Namodenoson Shows Promise in Bridging Liver Transplantation for Cirrhosis Patients — Can-Fite BioPharma Ltd.

Event summary

Can-Fite's Namodenoson treatment resolved ascites and regressed esophageal varices in a patient with decompensated cirrhosis, enabling successful bridging to liver transplantation.
The patient remained clinically stable for approximately 28 months before undergoing a successful liver transplant in January 2026.
Namodenoson is a selective A3 adenosine receptor agonist with anti-inflammatory and anti-fibrotic effects, currently in Phase 3 trials for advanced liver cancer and Phase 2b for MASH.
The case report was published in the Japanese Journal of Gastroenterology and Hepatology on September 9, 2026.

The big picture

Can-Fite's Namodenoson represents a novel approach to managing decompensated cirrhosis, a condition with limited therapeutic options. The successful bridging to liver transplantation highlights the potential of A3 adenosine receptor agonists in improving patient outcomes. This case report adds to the growing body of evidence supporting Namodenoson's clinical utility, which could enhance its market positioning and regulatory standing. The broader implications for liver disease treatment underscore the strategic importance of Can-Fite's pipeline in addressing unmet medical needs.

What we're watching

Clinical Validation: Whether the positive outcomes observed in this case report can be replicated in larger clinical trials, validating Namodenoson's potential as a therapeutic option for decompensated cirrhosis.
Regulatory Pathway: The pace at which Can-Fite can leverage this data to secure additional regulatory designations or accelerate the approval process for Namodenoson in liver disease indications.
Market Positioning: How Can-Fite positions Namodenoson in the competitive landscape of liver disease treatments, particularly given its ongoing trials in other indications like MASH and hepatocellular carcinoma.